[Clinical efficacy of Manlyman Spray on premature ejaculation].

Objective: To observe the clinical effect of Manlyman Spray in the treatment of premature ejaculation (PE).

Methods: From January 2021 to March 2022, a total of 123 patients with PE were enrolled in clinical observation. Manlyman Spray was sprayed on the surface of the glans penis, corona of the glans and frenulum of the penis qd for 4 weeks. Before and after medication and at 4 weeks after drug withdrawal, the intravaginal ejaculation latency time (IELT), Premature Ejaculation Diagnostic Tool (PEDT) scores and Chinese Index of Sexual Function for Premature Ejaculation (ClPE) scores of the patients were obtained and compared.

Results: Compared with the baseline, the IELT of the patients was significantly prolonged after 4 weeks of medication (［1.51 ± 0.42］ vs ［3.79 ± 1.69］ min, P < 0.05) and at 4 weeks after drug withdrawal (［1.51 ± 0.42］ vs ［3.55 ± 1.62］ min, P < 0.05), the PEDT scores were remarkably improved after 4 weeks of medication (14.0 ± 1.9 vs 7.7 ± 2.1, P < 0.05) and at 4 weeks after drug withdrawal (14.0 ± 1.9 vs 7.8 ± 2.0, P < 0.05), and so were the CIPE scores (9.0 ± 1.6 vs 20.0 ± 1.7, P < 0.05, and 9.0 ± 1.6 vs 17.3 ± 1.6, P < 0.05).

Conclusion: Manlyman Spray has a definite effect in the treatment of PE.